Metformin for Longevity: The TAME Trial and What We Are Actually Testing
Metformin is the most commonly prescribed diabetes medication in the world with an exceptional safety record built over 60 years. It is also one of the most studied potential longevity drugs in history - with observational evidence suggesting metformin-treated diabetics outlive non-diabetic controls. The TAME trial is the first attempt to directly test whether metformin slows aging in non-diabetic humans.
- Metformin activates AMPK, inhibits mitochondrial complex I, reduces hepatic glucose production, and decreases circulating IGF-1 and insulin - all mechanisms that overlap significantly with the molecular pathways activated by caloric restriction and exercise.
- A landmark observational study found that metformin-treated type 2 diabetics had lower all-cause mortality than matched non-diabetic controls who were not taking metformin - generating enormous excitement about metformin as a longevity drug.
- The TAME trial (Targeting Aging with MEtformin), led by Nir Barzilai at Albert Einstein, is the first FDA-accepted trial designed to test a drug's ability to delay the onset of age-related diseases collectively in non-diabetic humans. Results are expected in 2025 to 2026.
- Metformin's most significant longevity concern is its potential interaction with exercise-induced adaptation. Multiple RCTs have found that metformin blunts mitochondrial and muscle adaptations to aerobic exercise, reducing VO2 max improvement normally seen with training.
- Metformin depletes vitamin B12 in a dose- and duration-dependent manner via impaired ileal absorption. B12 deficiency causes peripheral neuropathy, cognitive impairment, and anemia. All patients on chronic metformin should supplement with methylcobalamin B12 and monitor serum B12 levels annually.
The story of metformin and longevity begins with an observation so surprising it seemed almost impossible. In 2014, researchers at Cardiff University analyzed health records of 78,241 type 2 diabetics on metformin, matching them with 78,241 non-diabetic controls. The result: the diabetics on metformin survived longer than the non-diabetic controls. People with a serious chronic disease, on medication, were outliving healthy people not on medication. The obvious implication - that metformin was providing a longevity benefit over and above its glucose-lowering effects - launched a decade of research and debate.1
Metformin's Mechanisms: Why It Might Slow Aging
Metformin's primary mechanism is inhibition of mitochondrial complex I in the liver, which reduces hepatic ATP production, activates AMPK, and suppresses gluconeogenesis. The downstream effects of AMPK activation extend far beyond glucose control: AMPK inhibits mTOR, activates autophagy, stimulates mitochondrial biogenesis via PGC-1 alpha, and promotes SIRT1 activation - precisely the same pathways activated by caloric restriction and exercise.2 Beyond AMPK, metformin reduces circulating IGF-1 and insulin, suppresses NF-kB-mediated inflammation, activates FOXO transcription factors, and appears to improve gut microbiome composition.3
The TAME Trial: Testing Aging Itself
The TAME trial represents a landmark in aging medicine - for the first time, the FDA agreed that aging itself could serve as a clinical trial target. TAME enrolled 3,000 participants aged 65 to 79 without diabetes, randomized to 1,500 mg/day of extended-release metformin or placebo for 6 years. The primary endpoint is a composite of the first occurrence of any of six age-related conditions: myocardial infarction, stroke, heart failure, cancer, dementia, and death. Results are expected in 2025 or 2026.4
"TAME is not a diabetes trial. It is a test of whether we can treat aging as a disease - and whether metformin is the first drug to pass that test."
Dr. Nir Barzilai, Albert Einstein College of Medicine, principal investigator, TAME trialThe Exercise Interaction: A Critical Concern
Multiple RCTs have found that metformin significantly attenuates the mitochondrial adaptations to aerobic exercise training - including reductions in VO2 max improvement, mitochondrial biogenesis, and mitochondrial respiration capacity. The leading mechanistic explanation is that metformin's AMPK activation paradoxically blunts the exercise-induced AMPK signaling cascade that drives mitochondrial adaptation.5 This is a major practical concern for any longevity-oriented individual who exercises, and has led many prominent longevity physicians to recommend against metformin in active individuals prioritizing exercise-induced fitness adaptation.
B12 Depletion: The Overlooked Side Effect
Metformin impairs absorption of vitamin B12 in the ileum in a dose- and duration-dependent manner. Studies consistently find that 10 to 30 percent of chronic metformin users develop B12 deficiency within 5 to 10 years. B12 deficiency causes peripheral neuropathy (often misattributed to diabetic neuropathy), cognitive impairment, anemia, and elevated homocysteine.6 Practical protocol: monitor serum B12 annually. Supplement with methylcobalamin (the active form, superior to cyanocobalamin) at 500 to 1,000 mcg/day.
This is a personal decision requiring physician involvement. The case for consideration: well-established safety, clear mechanistic basis, compelling observational data, accessibility. The case for waiting: no definitive human longevity RCT yet, significant exercise interference, B12 depletion risk, and GI side effects in 20 to 30 percent of users. Those who exercise aggressively tend to avoid it; those who are metabolically compromised or sedentary may have a more favorable risk-benefit profile. TAME results, when available, should substantially clarify this decision.
References
- 1Bannister CA, et al. "Can people with type 2 diabetes live longer than those without? A comparison of mortality in people initiated with metformin or sulphonylurea monotherapy." Diabetes, Obesity and Metabolism. 2014;16(11):1165-1173.
- 2Foretz M, et al. "Metformin: from mechanisms of action to therapies." Cell Metabolism. 2014;20(6):953-966.
- 3Barzilai N, et al. "Metformin as a tool to target aging." Cell Metabolism. 2016;23(6):1060-1065.
- 4Espeland MA, et al. "Targeting Aging with Metformin (TAME): trial design." Journal of Gerontology. 2020.
- 5Konopka AR, et al. "Metformin inhibits mitochondrial adaptations to aerobic exercise training in older adults." Aging Cell. 2019;18(1):e12880.
- 6Aroda VR, et al. "Long-term metformin use and vitamin B12 deficiency in the Diabetes Prevention Program Outcomes Study." JCEM. 2016.